Search Results - "Trigo Pérez, José Manuel"

SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition by Trigo Pérez, José Manuel, Garrido López, Pilar, Felip Font, Enriqueta, Isla Casado, Dolores

“…The purpose of this article is to provide updated recommendations for the diagnosis and treatment of patients non-small-cell lung cancer (NSCLC). The staging…”
Get full text

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study by Thomas, M., Ponce-Aix, S., Navarro, A., Riera-Knorrenschild, J., Schmidt, M., Wiegert, E., Kapp, K., Wittig, B., Mauri, C., Dómine Gómez, M., Kollmeier, J., Sadjadian, P., Fröhling, K -P, Huber, R.M., Wolf, M., Pall, Georg, Surmont, Veerle, Bosquee, Léon, Germonpré, Paul, Brückl, Wolfgang, Grah, Christina, Herzmann, Christian, Leistner, Rumo, Meyer, Andreas, Müller, Lothar, Schmalz, Oliver, Scholz, Christian, Schröder, Michael, Serke, Monika, Wesseler, Claas, Brandts, Christian, Kopp, Hans-Georg, Blau, Wolfgang, Griesinger, Frank, Campelo, Maria Rosario Garcia, Garcia, Yolanda Garcia, Perez, José Manuel Trigo

“…The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based TLR9 agonist, might foster innate and adaptive immune response and thus improve…”
Get full text

Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: A Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology by Pérez, José Manuel Trigo, García-Cosío, Mónica, García-Castaño, Almudena, Gomà, Montserrat, Mesia-Nin, Ricard, Ruiz-Bravo, Elena, Soria-Rivas, Ainara, Castillo, Paola, Braña-García, Irene, Alberola-Ferranti, Margarita

“…The treatment of head and neck and salivary gland tumours is complicated and is constantly evolving. Prognostic and predictive indicators of response to…”
Get more information

616 Pharmacokinetics and safety of a subcutaneous formulation of nivolumab (NIVO SC) monotherapy: updated results from the phase 1/2 CheckMate 8KX study by Lonardi, Sara, Ługowska, Iwona, O’Donnell, Anne, Jackson, Christopher, Latten-Jansen, Loes Maria, North, Richard, Salvo, Marcelo Garrido, Santoro, Armando, Chacón, Matías, Li, Linghui, Joseph, Devanand, Gibson, Elizabeth, Bennett, Bryan, Gurm, Balmeet, Ng, Wee-Teck, Donald Harvey, R, Trigo Pérez, José Manuel, Calvo, Aitana

“…BackgroundNIVO administered via intravenous (IV) infusion is a transformative immuno-oncology therapy across multiple tumor types. However, there remains an…”
Get full text

370 Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial by Pothuri, Bhavana, Berton, Dominique, Moreno, Victor, Oaknin, Ana, Trigo Perez, Jose Manuel, Curigliano, Giuseppe, Ellard, Susan, Pikiel, Joanna, Banerjee, Susana, Barretina-Ginesta, Maria-Pilar, Miller, Rowan, Tinker, Anna, Jewell, Andrea, Plummer, Ruth, Joly, Florence, Veneris, Jennifer, Duan, Tao, Andre, Thierry

“…BackgroundDostarlimab is a humanized programmed death 1 (PD-1) receptor monoclonal antibody that blocks interaction with the ligands PD-L1 and PD-L2…”
Get full text

Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study by Andre, Thierry, Berton, Dominique, Curigliano, Giuseppe, Ellard, Susan, Trigo Pérez, Jose Manuel, Arkenau, Hendrik-Tobias, Abdeddaim, Cyril, Moreno, Victor, Guo, Wei, Im, Ellie, Starling, Naureen

“…Abstract only 9 Background: Dostarlimab is a humanized anti–PD-1 monoclonal antibody that binds the PD-1 receptor, blocking interaction with ligands PD-L1 and…”
Get full text

362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis by Spicer, James, Helland, Åslaug, Carcereny, Enric, Arriola, Edurne, Gomez, Manuel Dómine, Trigo Perez, Jose Manuel, Thompson, Jonathan, Strauss, James, Ortega Granados, Ana Laura, Felip, Enriqueta, Schmidt, Emmett, Chisamore, Michael, Madeleine, Noelly, Rayford, Austin, Lorens, Katherine, Siddiqui, Abdul, Gabra, Hani, Nautiyal, Jaya, Micklem, David, Lorens, James, Krebs, Matthew

“…BackgroundAXL is implicated in resistance to immunotherapy. Bemcentinib (BGB324), a first-in-class, oral, selective and potent AXL kinase inhibitor, enhances…”
Get full text

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer by Butts, Charles Andrew, Socinski, Mark A., Mitchell, Paul, Thatcher, Nick, Havel, Libor, Krzakowski, Maciej Jerzy, Nawrocki, Sergiusz, Ciuleanu, Tudor-Eliade, Bosquée, Lionel, Trigo Perez, Jose Manuel, Spira, Alexander I., Tremblay, Lise, Nyman, Jan, Ramlau, Rodryg, Helwig, Christoph, Falk, Martin H., Shepherd, Frances A.

“…Abstract only 7500 Background: L-BLP25 is a MUC1 antigen specific cancer immunotherapy. We report results from the phase III START study of L-BLP25 in patients…”
Get full text

Rechallenge with immune checkpoint inhibitors beyond severe toxicities, an utopia? by Medina Rodriguez, Laura, Jimenez-Rodriguez, Begona, Llácer, Casilda, Trigo Perez, Jose Manuel Manuel

“…e14601 Background: Immunotherapy (IO) has substantially improved clinical outcomes in different types of tumours. Its use has been associated with so-called…”
Get full text

AMBER parts 1c and 1e: A phase 1 study of cobolimab plus dostarlimab in patients (pts) with advanced/metastatic melanoma by Ribas, Antoni, Eroglu, Zeynep, Trigo Perez, Jose Manuel Manuel, Di Pace, Brian, Wang, Tianli, Ghosh, Srimoyee, Dhar, Arindam, Borgovan, Theo, Waszak, Angela, Davar, Diwakar

“…9513 Background: TIM-3 and PD-1 are markers of T-cell suppression that are upregulated in melanoma. AMBER (NCT02817633) is evaluating cobolimab…”
Get full text

Safety analysis of lurbinectedin versus topotecan in elderly patients by Subbiah, Vivek, Lorusso, Domenica, Trigo Perez, Jose Manuel Manuel, Leary, Alexandra, Moreno, Victor, Kristeleit, Rebecca, Vergote, Ignace, Lopez-Vilariño, Jose Antonio, Fernandez, Cristian Marcelo, Siguero, Mariano, Kahatt, Carmen Maria, Zeaiter, Ali Hassan, Boni, Valentina, Navarro, Alejandro, Gutierrez Calderon, Vanesa, Pardo, Beatriz, Berton, Dominique, Scambia, Giovanni

“…e20632 Background: Lurbinectedin is a selective inhibitor of oncogenic transcription. The US FDA granted accelerated approval for lurbinectedin as monotherapy…”
Get full text

Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC by Cousin, Sophie, Paz-Ares, Luis G., Fülöp, Andrea, Horvath, Ildiko, Trigo Perez, Jose Manuel Manuel, Zugazagoitia, Jon, Bonanno, Laura, Lopez-Vilariño, Jose Antonio, Kahatt, Carmen Maria, Fernandez, Cristian Marcelo, Gomez, Javier, Zeaiter, Ali Hassan, Navarro, Alejandro, Syrigos, Kostas N., Smit, Egbert, Ciuleanu, Tudor-Eliade, Chiappori, Alberto, Lopez-Lopez, Rafael, Besse, Benjamin

“…8591 Background: Relapsed SCLC is a difficult-to-treat disease. A considerable number of SCLC patients are elderly with associated fragility and numerous…”
Get full text

Lurbinectedin in patients with pretreated BRCA 1/2-associated metastatic breast cancer: Results from a phase II basket study by Boni, Valentina, Pistilli, Barbara, Brana, Irene, Shapiro, Geoffrey, Trigo Perez, Jose Manuel Manuel, Moreno, Victor, Castellano, Daniel E., Fernandez, Cristian Marcelo, Kahatt, Carmen Maria, Alfaro, Vicente, Siguero, Mariano, Zeaiter, Ali Hassan, Longo, Federico, Zaman, Khalil, Antón Torres, Antonio, Paredes Lario, Alfredo, Huidobro Vence, Gerardo, Subbiah, Vivek

“…1092 Background: Lurbinectedin (L) is a selective inhibitor of oncogenic transcription that leads to cell apoptosis and shows antitumor activity against…”
Get full text

MP52-04 2-YEAR FOLLOW-UP OF RADIUM-223 RE-TREATMENT IN AN INTERNATIONAL, OPEN-LABEL, PHASE 1/2 STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER AND BONE METASTASES by Mariados, Neil, Sartor, Oliver, Heinrich, Daniel, Méndez Vidal, Maria José, Keizman, Daniel, Thellenberg Karlsson, Camilla, Peer, Avivit, Procopio, Giuseppe, Frank, Stephen J., Pulkkanen, Kalevi, Rosenbaum, Eli, Severi, Stefano, Trigo Perez, Jose Manuel, Trandafir, Lucia, Wagner, Volker, Li, Rui, Nordquist, Luke T.

Get full text

Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial by Paz-Ares, Luis G., Trigo Perez, Jose Manuel, Besse, Benjamin, Moreno, Victor, Lopez, Rafael, Sala, Maria Angeles, Ponce Aix, Santiago, Fernandez, Cristian Marcelo, Siguero, Mariano, Kahatt, Carmen Maria, Zeaiter, Ali Hassan, Zaman, Khalil, Boni, Valentina, Arrondeau, Jennifer, Martinez Aguillo, Maite, Delord, Jean-Pierre, Awada, Ahmad, Kristeleit, Rebecca Sophie, Olmedo Garcia, Maria Eugenia, Subbiah, Vivek

“…Abstract only 8506 Background: Lurbinectedin (L) is a novel anticancer drug that inhibits activated transcription and induces DNA double-strand breaks, leading…”
Get full text

A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy by Felip, Enriqueta, Brunsvig, Paal, Vinolas, Nuria, Ponce Aix, Santiago, Carcereny Costa, Enric, Dómine Gomez, Manuel, Trigo Perez, Jose Manuel, Arriola, Edurne, Campelo, Rosario Garcia, Spicer, James F., Thompson, Jonathan Robert, Ortega Granados, Ana Laura, Holt, Robert J, Lorens, Katherine, Lorens, James B., Shoaib, Muhammad, Siddiqui, Abdul, Schmidt, Emmett V., Chisamore, Michael Jon, Krebs, Matthew

“…Abstract only 9098 Background: AXL is an RTK implicated in epithelial-to-mesenchymal transition and as a resistance mechanism to multiple therapies including…”
Get full text

Anti-PD-1 antibody cetrelimab (JNJ-63723283) in patients with advanced cancers: Updated phase I/II study results by Rutkowski, Piotr, Felip, Enriqueta, Moreno, Victor, Trigo Perez, Jose Manuel, Calvo, Aitana, Kowalski, Dariusz, Cortinovis, Diego, Lee, James J., Manikhas, George, Plummer, Elizabeth Ruth, Maio, Michele, Ascierto, Paolo Antonio, Vladimirov, Vladimir Ivanovich, Gaffney, Dana, Li, Lilian Y., Bae, Kyounghwa, Greger, James G., Shin, Chu Ri, Xie, Hong, Calvo, Emiliano

“…Abstract only 31 Background: Cetrelimab (JNJ-63723283) is an IgG4, anti-programmed cell death protein-1 (PD-1) antibody. Here we present updated results from…”
Get full text

Clinical utility of plasma-based digital next-generation sequencing (NGS) in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping by Zugazagoitia, Jon, Ramos Garcia, Inmaculada, Trigo Perez, Jose Manuel, Palka, Magda, Gómez Rueda, Ana, Jantus-Lewintre, Eloisa, Camps, Carlos, Isla, Dolores, Ponce Aix, Santiago, Campelo, Rosario Garcia, Provencio-Pulla, Mariano, Bernabe Caro, Reyes, Juan Vidal, Oscar, Felip, Enriqueta, De Castro, Javier, Sanchez Torres, Jose Miguel, Faull, Iris, Lanman, Richard B., Garrido Lopez, Pilar, Paz-Ares, Luis G.

“…Abstract only…”
Get full text

Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study by Trigo Perez, Jose Manuel, Leary, Alexandra, Besse, Benjamin, Castellano, Daniel E., Ponce Aix, Santiago, ARRONDEAU, Jennifer, Moreno, Victor, Doger, Bernard, Lopez, Rafael, Awada, Ahmad, Jungels, Christiane, Forster, Martin David, Boni, Valentina, Lardelli, Pilar, Siguero, Mariano, Kahatt, Carmen Maria, Soto-Matos, Arturo, Kristeleit, Rebecca Sophie

“…Abstract only…”
Get full text

Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC by Lorens, James, Arce-Lara, Carlos Eduardo, Arriola, Edurne, Brunsvig, Paal, Carcereny Costa, Enric, Domine, Manuel, Dragnev, Konstantin H., Felip, Enriqueta, Campelo, Rosario Garcia, Krebs, Matthew, Ponce Aix, Santiago, Spicer, James F., Trigo Perez, Jose Manuel, Vinolas, Nuria, Holt, Robert J, Brown, Anthony, Chisamore, Michael Jon

“…Abstract only…”
Get full text